<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04991454</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00107613</org_study_id>
    <nct_id>NCT04991454</nct_id>
  </id_info>
  <brief_title>Xenon MRI Pulm Hypertension</brief_title>
  <acronym>Jupiter PH</acronym>
  <official_title>Xenon MRI in Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bastiaan Driehuys</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective outlined in this study is to determine how pulmonary vascular&#xD;
      remodeling in PAH at a cellular and pathological level is associated with changes in gas&#xD;
      exchange physiology and hemodynamics (monitored with 129Xe MRI/MRS) and how these signals&#xD;
      change with disease progression or treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In aim 1, the study team will compare 129Xe MRI signatures to lung explant pathology,&#xD;
      cellular identity from single-cell RNA sequencing, and cellular phenotypes in gas exchange&#xD;
      defects to areas that are spared, which the team will hypothesize are exposed to lower levels&#xD;
      of hemodynamic shear stress. This will be done by performing 129Xe MRI scans in fifteen&#xD;
      subjects (cohort 1) with PAH awaiting a lung transplant, followed by a pathologic assessment&#xD;
      (with usual histopathology and single cell RNA sequencing) of the subject's explanted lung&#xD;
      after transplant. The study team expect that areas of proliferation and fibrosis will&#xD;
      correlate with 129Xe MRI gas exchange and spectroscopic defects&#xD;
&#xD;
      In aim 3, The study team will test whether directly monitoring lung pathology with 129Xe MRI&#xD;
      will provide additional prognostic information to standard-of-care clinical monitoring in 45&#xD;
      subjects (cohort 2). At 6-month follow-up appointments, standard-of-care assessments&#xD;
      including labs, echocardiography, and six-minute walk distance and 129Xe MRI will be&#xD;
      collected. The study team expect that In aim 1, the study team will compare 129Xe MRI&#xD;
      signatures to lung explant pathology, cellular identity from single-cell RNA sequencing, and&#xD;
      cellular phenotypes in gas exchange defects to areas that are spared, which the study team&#xD;
      hypothesizes are exposed to lower levels of hemodynamic shear stress. This will be done by&#xD;
      performing 129Xe MRI scans in fifteen subjects (cohort 1) with PAH awaiting a lung&#xD;
      transplant, followed by a pathologic assessment (with usual histopathology and single-cell&#xD;
      RNA sequencing) of the subject's explanted lung after transplant. The study team expect that&#xD;
      areas of proliferation and fibrosis will correlate with 129Xe MRI gas exchange and&#xD;
      spectroscopic defects&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pulmonary vascular remodeling</measure>
    <time_frame>5 years</time_frame>
    <description>The study team will determine whether the correlation between Red Blood Cell Signal from Xenon MRI to pathologic scoring of pulmonary vascular remodeling from histopathology is statistically significant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Red Blood Cell Signal from Xenon MRI</measure>
    <time_frame>5 years</time_frame>
    <description>We will determine whether the correlation between Red Blood Cell Signal from Xenon MRI to six minute walk distance, tricuspid annular plane excursion and right ventricular systolic pressure in longitudinal follow-up of PAH patients is statistically significant.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>end-stage pulmonary arterial hypertension .</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>subjects with end-stage PAH that currently on the waitlist for lung transplant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>following pulmonary arterial hypertension subjects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Following pulmonary arterial hypertension subjects upto 24 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>129Xe Hyperpolarized</intervention_name>
    <description>Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC), as is the case for all protocols currently carried out under IND 109,490.</description>
    <arm_group_label>end-stage pulmonary arterial hypertension .</arm_group_label>
    <arm_group_label>following pulmonary arterial hypertension subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria of Cohort 1&#xD;
&#xD;
        Subjects must meet all of the following inclusion criteria to be eligible for enrollment&#xD;
        into the trial:&#xD;
&#xD;
          1. Outpatients of either gender, Age 18-75&#xD;
&#xD;
          2. Awaiting a lung transplant&#xD;
&#xD;
          3. Diagnosis of Group 1 PH using the criteria from previous clinical trials (right heart&#xD;
             catheterization demonstrating hemodynamic criteria of a mean pulmonary artery pressure&#xD;
             (mPAP) ≥ 25 mmHg, pulmonary vascular resistance ≥ 3 WU, pulmonary capillary wedge&#xD;
             pressure ≤ 15 mmHg)&#xD;
&#xD;
          4. Willing and giving informed consent and adhere to visit/protocol schedules (consent&#xD;
             must be given before any study procedures are performed).&#xD;
&#xD;
          5. Women of childbearing potential must have a negative urine pregnancy test before MRI&#xD;
&#xD;
        Exclusion Criteria of Cohort 1&#xD;
&#xD;
        Subjects presenting with any of the following will not be included in the trials:&#xD;
&#xD;
          1. Pulmonary Veno-occlusive disease or Porto-pulmonary hypertension&#xD;
&#xD;
          2. Moderate to severe heart disease (LVEF &lt;45%, Severe LV hypertrophy, Moderate to severe&#xD;
             valvular disease)&#xD;
&#xD;
          3. PH due to schistosomiasis&#xD;
&#xD;
          4. Sarcoidosis&#xD;
&#xD;
          5. Active cancer&#xD;
&#xD;
          6. Sickle cell anemia&#xD;
&#xD;
          7. Liver disease (Childs-Pugh class C)&#xD;
&#xD;
          8. Prisoners and pregnant women will not be approached for the study&#xD;
&#xD;
          9. Conditions that will prohibit MRI scanning (metal in eye, claustrophobia, inability to&#xD;
             lie supine)&#xD;
&#xD;
         10. Medical or psychological conditions which, in the opinion of the investigator, might&#xD;
             create undue risk to the subject or interfere with the subject's ability to comply&#xD;
             with the protocol requirements&#xD;
&#xD;
        Inclusion Criteria of Cohort 2&#xD;
&#xD;
        Subjects must meet all of the following inclusion criteria to be eligible for enrollment&#xD;
        into the trial:&#xD;
&#xD;
          1. Treatment naïve or treatment started within the last 3 months&#xD;
&#xD;
          2. Outpatients of either gender, Age 18-75&#xD;
&#xD;
          3. WHO functional class (FC) 2-3 symptoms with a diagnosis of group 1 PH (mean pulmonary&#xD;
             artery pressures (mPAP) &gt; 20 mmHg, pulmonary capillary wedge pressure (PCWP) ≤ 15mmHg&#xD;
             and pulmonary vascular resistance (PVR) ≥3 WU)&#xD;
&#xD;
          4. Willing and able to give informed consent and adhere to visit/protocol schedules&#xD;
             (consent must be given before any study procedures are performed).&#xD;
&#xD;
          5. Women of childbearing potential must have a negative urine pregnancy test before MRI&#xD;
&#xD;
        Exclusion Criteria of Cohort 2&#xD;
&#xD;
        Subjects presenting with any of the following will not be included in the trials:&#xD;
&#xD;
          1. Sarcoidosis&#xD;
&#xD;
          2. Active cancer&#xD;
&#xD;
          3. Sickle cell anemia&#xD;
&#xD;
          4. Liver disease (Childs-Pugh class C)&#xD;
&#xD;
          5. Any conditions that prevent the performance of 129Xe MRI scans.&#xD;
&#xD;
          6. Prisoners and pregnant women will not be approached for the study.&#xD;
&#xD;
          7. Conditions that will prohibit MRI scanning (metal in eye, claustrophobia, inability to&#xD;
             lie supine).&#xD;
&#xD;
          8. Medical or psychological conditions which, in the opinion of the investigator, might&#xD;
             create undue risk to the subject or interfere with the subject's ability to comply&#xD;
             with the protocol requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sudarshan Rajagopal, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samantha Womack, MS</last_name>
    <phone>9196818439</phone>
    <email>sam.womack@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susana Almeida-Peters, RN BSN</last_name>
    <phone>9196846237</phone>
    <email>susana.almeida-peters@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susana Almeida-Peters, RN</last_name>
      <phone>919-668-2642</phone>
      <email>susana.almeida-peters@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Samantha Womack</last_name>
      <phone>919-684-7931</phone>
      <email>Samantha.Womack@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sudarshan Rajagopal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bastiann Driehays, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 7, 2021</study_first_submitted>
  <study_first_submitted_qc>July 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Bastiaan Driehuys</investigator_full_name>
    <investigator_title>Associate Professor of Radiology</investigator_title>
  </responsible_party>
  <keyword>Lung Transplant</keyword>
  <keyword>Xenon</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

